Wegovy 25 — Semaglutide 25 mg Tablets, 30 Tablets

Wegovy 25 mg is supplied in the form of oral tablets.

Qualitative and Quantitative Composition per Tablet:

• • Active Ingredient: Semaglutide — 25 mg.
• • Excipients: Salcaprozate sodium (SNAC), microcrystalline cellulose, magnesium stearate, tablet coating agents.

Packaging and Presentation: Round, biconvex tablets bearing "25" debossing. Each box contains 30 tablets. The outer carton reflects official Novo Nordisk branding featuring the corporate bull logo, generic name semaglutide, brand name wegovy, strength 25 mg, and administration details Oral use / 30 tablets.

Pharmacodynamics:
Semaglutide is a long-acting GLP-1 analogue with 94% human peptide homology. It binds to and activates GLP-1 receptors. Semaglutide increases insulin secretion and lowers glucagon secretion in a glucose-dependent manner. Weight loss mechanisms involve appetite reduction, decreased hunger, enhanced satiety, and delayed gastrointestinal motility.

Pharmacokinetics:

• • Absorption: Oral semaglutide absorption occurs primarily in the stomach. Peak plasma concentrations are reached 1 hour post-dose. The SNAC absorption enhancer facilitates gastric mucosal transport.
• • Distribution: High volume of distribution. Semaglutide is extensively bound to plasma proteins (>99%).
• • Metabolism: Metabolized via proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid side chain.
• • Elimination: Eliminated primarily via renal and fecal excretion. The terminal half-life is approximately 1 week, supporting once-daily dosing to maintain steady-state concentrations.

Wegovy 25 mg is indicated in adult patients for:

• • Chronic Weight Management: As an adjunct to a reduced-calorie diet and increased physical activity for adult patients with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 to < 30 kg/m2) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
• • Cardiovascular Risk Reduction: To reduce major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity.

Wegovy 25 mg is taken orally once daily following strict protocols:

• • Timing and Conditions: Take in the morning on an empty stomach immediately upon waking. Swallow the tablet whole with no more than 120 ml of water.
• • Post-Dosing Restrictions: Do not eat, drink, or take any other oral medications for 30 minutes following administration, as this interferes with drug absorption.

Titration and Maintenance Regimen:
The 25 mg strength is administered as the target maintenance dose starting from month 4 (day 91+). The complete dose escalation schedule is: 1.5 mg (first 30 days) → 4 mg (month 2) → 9 mg (month 3) → 25 mg (ongoing maintenance dose).

Administration of Wegovy 25 mg is contraindicated in:

• • Hypersensitivity: Known hypersensitivity to semaglutide or any inactive excipient.
• • Oncological History: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• • Pregnancy and Lactation: Contraindicated in pregnant or nursing women.
• • Severe Gastrointestinal Disease: Severe gastroparesis or acute inflammatory bowel disease flare-ups.
• • Pediatric Population: Safety and efficacy in individuals under 18 years of age have not been established.

Potential drug interactions should be evaluated during oral semaglutide therapy:

• • Absorption Impacts: Oral semaglutide may affect the pharmacokinetics of concomitant oral drugs due to delayed gastric emptying. Strict adherence to the 30-minute fasting window minimizes risks.
• • Narrow Therapeutic Index Drugs: Caution is advised when co-administering drugs requiring careful concentration monitoring (e.g., levothyroxine, warfarin).
• • Insulin and Secretagogues: Co-administration with insulin or sulfonylureas increases the risk of hypoglycemia.

Pregnancy:
Wegovy 25 mg is strictly contraindicated during pregnancy. Semaglutide poses potential fetal risks. Pregnancy planning requires discontinuing treatment at least 2 months prior to planned conception due to prolonged drug washout periods.

Lactation:
Data regarding human breast milk excretion are unavailable. The drug is contraindicated during breastfeeding.

The most frequent adverse events associated with GLP-1 receptor agonists involve the gastrointestinal tract, diminishing in intensity as the body adapts to the maintenance dose:

• • Gastrointestinal Tract (Very Common): Nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, gastritis, flatulence, eructation, gastroesophageal reflux.
• • Metabolic Disorders: Decreased appetite, hypoglycemia (in diabetic patients).
• • Nervous System: Dizziness, fatigue, headache.
• • Cardiovascular System: Resting heart rate increases (sinus tachycardia).
• • Other: Pancreatic enzyme elevations (lipase and amylase), cholelithiasis.

Symptoms:
Overdose may result in pronounced adverse reactions, primarily gastrointestinal (severe nausea, vomiting, acute abdominal pain), along with a risk of symptomatic hypoglycemia.

Treatment:
No specific antidote exists. Supportive and symptomatic care should be administered, monitoring blood glucose and fluid-electrolyte balance. Hemodialysis is ineffective due to high plasma protein binding.

Storage Requirements for Wegovy 25 mg:

• 🌡️ Temperature Range: Store in a dry place protected from light at temperatures not exceeding 25–30 °C (77–86 °F). Do not freeze.
• ☀️ Moisture Protection: Keep in original closed packaging to protect tablets from moisture.
• 👶 Safety Precautions: Keep out of reach of children.
• ⏳ Shelf Life: Stated on the outer carton. Do not use past expiration date. Prescription-only medicine.

To verify the authenticity of original Wegovy 25 mg manufactured by Novo Nordisk, check the following visual and security features:

• ✅ Novo Nordisk Corporate Logo: Recognizable horned bull corporate logo located in the bottom right carton corner.
• ✅ Product Branding: Brand name "wegovy" printed in lowercase letters with a trademark symbol, accompanied by strength "25 mg" set inside a turquoise rectangular block.
• ✅ Carton Design: Clean white background complemented by smooth turquoise graphic wave accents and text reading Oral use / 30 tablets.
• ✅ Tablet Depiction: Graphic illustration of a round grey tablet featuring "25" debossing printed on the front box face.
• ✅ Security Features: Presence of 2D DataMatrix barcodes, serial numbers, and tamper-evident carton seals.